Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

The discovery of numerous noncoding RNA (ncRNA) transcripts in species from yeast to
mammals has dramatically altered our understanding of cell biology, especially the biology …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

There is substantial heterogeneity among primary prostate cancers, evident in the spectrum
of molecular abnormalities and its variable clinical course. As part of The Cancer Genome …

While mutations affecting protein-coding regions have been examined across many
cancers, structural variants at the genome-wide level are still poorly defined. Through …

Prostate cancer is the second most common cancer in men worldwide and causes over
250,000 deaths each year. Overtreatment of indolent disease also results in significant …

The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …

Transcriptomics studies often rely on partial reference transcriptomes that fail to capture the
full catalogue of transcripts and their variations. Recent advances in sequencing …

Prostate cancer is the second most common cause of male cancer deaths in the United
States. However, the full range of prostate cancer genomic alterations is incompletely …

Despite much recent progress, prostate cancer continues to represent a major cause of
cancer-related mortality and morbidity in men. Since early studies on the role of the …